RESUMEN
BACKGROUND AND OBJECTIVES: Peach gibberellin-regulated protein (peamaclein) has recently emerged as a relevant food allergen in cypress pollen-hypersensitive patients. Objective: We investigated monosensitization to peamaclein among Italian cypress pollen-allergic patients. MATERIAL AND METHODS: A total of 835 cypress pollen-hypersensitive patients from 28 Italian allergy centers underwent a thorough work-up to determine food-allergic reactions and performed skin prick testing with a commercial peach extract containing peamaclein. IgE to rPru p 3 was measured in peach reactors, and those with negative results were enrolled as potentially monosensitized to peamaclein. IgE reactivity to rPru p 7 was evaluated using immunoblot and an experimental ImmunoCAP with rPru p 7. RESULTS: Skin prick tests were positive to peach in 163 patients (19.5%); however, 127 (77.9%) were excluded because they reacted to Pru p 3. Twenty-four patients (14.7%) corresponding to 2.8% of the entire study population) were considered potentially monosensitized to peamaclein. No geographic preference was observed. Seventeen of the 24 patients (70.8%) had a history of food allergy, mainly to peach (n=15). Additional offending foods included other Rosaceae, citrus fruits, fig, melon, tree nuts, and kiwi. On peach immunoblot, only 3 of 18 putative peamaclein-allergic patients reacted to a band at about 7 kDa; an additional 4 patients reacted at about 50-60 kDa. Ten of 18 patients (56%) had a positive result for Pru p 7 on ImmunoCAP. CONCLUSION: Allergy and sensitization to peamaclein seem rare in Italy. Most patients react to peach, although other Rosaceae fruits and several citrus fruits may also be offending foods. Peach and cypress pollen probably also share cross-reacting allergens other than peamaclein.
Asunto(s)
Cupressus , Hipersensibilidad a los Alimentos , Alérgenos/efectos adversos , Antígenos de Plantas/efectos adversos , Reacciones Cruzadas , Hipersensibilidad a los Alimentos/epidemiología , Giberelinas , Humanos , Inmunoglobulina E , Proteínas de Plantas/efectos adversos , Polen , Pruebas Cutáneas/efectos adversosRESUMEN
Summary: Background and Objective. Sensitization and allergy to shrimp among Italian house dust mite allergic patients are not well defined and were investigated in a large multicenter study. Methods. Shrimp sensitization and allergy were assessed in 526 house dust mite (HDM)-allergic patients submitted to the detection of IgE to Der p 10 and 100 atopic control not sensitized to HDM. Results. Shrimp allergy occurred in 9% of patients (vs 0% of 100 atopic controls not sensitized to HDM; p minor 0.001). Shrimp-allergic patients were less frequently hypersensitive to airborne allergens other than HDM than crustacean-tolerant subjects (35% vs 58.8%; p minor 0.005). Only 51% of tropomyosin-sensitized patients had shrimp allergy, and these showed significantly higher Der p 10 IgE levels than shrimp-tolerant ones (mean 22.2 KU/l vs 6.2 KU/l; p minor 0.05). Altogether 53% of shrimp-allergic patients did not react against tropomyosin. Conclusions. Shrimp allergy seems to occur uniquely in association with hypersensitivity to HDM allergens and tropomyosin is the main shrimp allergen but not a major one, at least in Italy. Along with tropomyosin-specific IgE levels, monosensitization to HDM seems to represent a risk factor for the development of shrimp allergy among HDM allergic patients.
Asunto(s)
Antígenos Dermatofagoides/inmunología , Proteínas de Artrópodos/inmunología , Hipersensibilidad a los Alimentos/epidemiología , Tropomiosina/inmunología , Adolescente , Adulto , Animales , Reacciones Cruzadas , Femenino , Hipersensibilidad a los Alimentos/inmunología , Humanos , Inmunoglobulina E/metabolismo , Italia/epidemiología , Masculino , Persona de Mediana Edad , Penaeidae , Prevalencia , Pyroglyphidae , Adulto JovenRESUMEN
SUMMARY: Background. The term of α-Gal syndrome, which includes the delayed allergy to red meat and the allergic reactions following the administration of cetuximab, is associated to the presence of specific IgE to α-Gal. In Italy, only anecdotal cases were reported so far. The Association of Italian Allergists (AAITO) carried out a survey with the aim of evaluating presence, characteristics, clinical features, and distribution of the syndrome in Italy. Methods. A web structured questionnaire was made available on the website of AAIITO from July 2016 to January 2017. It included 31 multiple-choice questions concerning different items, including the site of physicians, the number of patients diagnosed as having cetuximab allergy and/or delayed red meat allergy, recall of tick bites, symptoms, time to reactions, elicitor foods, reactions with foods other than meat, and in-vivo and in-vitro tests used for the diagnosis. Results. Seventy-nine physicians completed the questionnaire. Nine cases of allergy to cetuximab and 40 cases of delayed red meat allergy were recorded across Italy. 22.5% of patients with cetuximab allergy and 62.5% of those with delayed red meat allergy recalled a tick bite. 75% of patients with delayed red meat allergy experienced symptoms after eating beef (butcher's cut in 72.5%). Urticaria was the most frequent clinical manifestation (65% of cases). In 60.6% of cases symptoms appeared 2 - 4 hours after meat ingestion, while in 7.9% symptoms appeared after > 4 hours. The most used diagnostic methods were the intradermal test for cetuximab allergy (88.9%) and the detection of IgE to α-Gal (55.5%) for red meat allergy. Most case reports came from Northern Italy. Conclusions. α-Gal syndrome is present in Italy and beef is the most frequent offending food. In most cases symptoms were not severe.
Asunto(s)
Cetuximab/efectos adversos , Disacáridos/inmunología , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad Tardía/inmunología , Carne Roja/efectos adversos , Mordeduras de Garrapatas/inmunología , Cetuximab/inmunología , Reacciones Cruzadas , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/epidemiología , Hipersensibilidad a los Alimentos/diagnóstico , Hipersensibilidad a los Alimentos/epidemiología , Encuestas Epidemiológicas , Humanos , Hipersensibilidad Tardía/diagnóstico , Hipersensibilidad Tardía/epidemiología , Pruebas Inmunológicas , Italia/epidemiología , Pronóstico , Factores de Riesgo , Síndrome , Mordeduras de Garrapatas/diagnóstico , Mordeduras de Garrapatas/epidemiologíaRESUMEN
Allergic reactions to mannitol have been reported rarely, despite its widespread use as a drug and as a food excipient. This is the first case report in which oral mannitol induces an immediate type hypersensitivity as a drug excipient, in a 42 year old man affected by rhinitis to olive tree pollen. Unusual and undervalued risk factors for mannitol hypersensitivity are examined.
Asunto(s)
Hipersensibilidad a las Drogas/etiología , Excipientes/efectos adversos , Hipersensibilidad Inmediata/etiología , Manitol/efectos adversos , Administración Oral , Corticoesteroides/uso terapéutico , Adulto , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/tratamiento farmacológico , Excipientes/administración & dosificación , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Hipersensibilidad Inmediata/diagnóstico , Hipersensibilidad Inmediata/tratamiento farmacológico , Pruebas Inmunológicas , Masculino , Manitol/administración & dosificación , Valor Predictivo de las Pruebas , Factores de Riesgo , Resultado del TratamientoAsunto(s)
Angioedema/inducido químicamente , Erupciones por Medicamentos/etiología , Hidrocortisona/análogos & derivados , Inmunoglobulina E/inmunología , Reaginas/inmunología , Urticaria/inducido químicamente , Anciano , Anafilaxia/inducido químicamente , Anafilaxia/inmunología , Angioedema/inmunología , Antiinflamatorios no Esteroideos/efectos adversos , Bronquitis/tratamiento farmacológico , Erupciones por Medicamentos/inmunología , Femenino , Humanos , Hidrocortisona/efectos adversos , Hidrocortisona/inmunología , Memoria Inmunológica , Inyecciones Intramusculares , Pruebas Intradérmicas , Masculino , Hemisuccinato de Metilprednisolona , Sulfonamidas , Factores de Tiempo , Urticaria/inmunologíaRESUMEN
Glucocorticoids (GCs) represent the most effective treatment for autoimmune and allergic diseases, even if collateral effects are not rare, especially endocrine and immunosuppressive manifestations. Moreover, these drugs can develop adverse immunological reactions of I, III or IV type. Though immediate adverse reactions caused by systemic therapy with GCs are not very frequent, the possible beginning of anaphylactic and pseudo-anaphylactic manifestations in patients undergoing therapy with these drugs has to be considered. It has been observed that immediate adverse reactions usually are happened in asthmatic patients and in patients obliged to assume GCs again and again because of their pathology (e.g, kidney transplant). Other risk factors resulted to be female sex and hypersensibility to acetylsalicylic acid (ASA). Both in the cases of pseudo-allergic and allergic reactions, the pharmacological principle is hardly the responsible agent for the reaction; instead the excipients in drugs are often implicated (succinate salt, sulphites and carboxy-methyl-cellulose). It is possible that the IgE-response is highly specific for a fixed GC molecule as well depending on the way of administration and its salification. Moreover, it has been hypothesized that in patients with a first type allergic reaction to GCs there is a fourth type, sensitization to GCs, which is not usually diagnosed and even comes before IgE sensitization. Third type hypersensibility reactions may occur, too. Since GCs are large-scale drugs, also in emergency medicine and reanimation, allergic sensitization towards them, although infrequent, gives many interventionist problems. In the light of this feature, it seems of crucial importance to verify the tolerance toward other GC molecules. And in particular, it has been noted that patients presenting immediate reactions to hydrocortisone (HC) and methylprednisolone (MP) could tolerate prednisone and prednisolone per os and second-generation GCs, such as desamathazone and betamethazone. Nevertheless, second-generation GCs must not be considered safe; in fact, the beginning of allergic manifestations has been pointed out even towards them.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Hipersensibilidad a las Drogas/inmunología , Glucocorticoides/efectos adversos , Ensayos Clínicos como Asunto , Hipersensibilidad a las Drogas/tratamiento farmacológico , Hipersensibilidad a las Drogas/etiología , Humanos , Hipersensibilidad Inmediata/inmunologíaAsunto(s)
Alopurinol/efectos adversos , Diuréticos/efectos adversos , Hipersensibilidad a las Drogas/etiología , Gota/tratamiento farmacológico , Corticoesteroides/administración & dosificación , Agonistas Adrenérgicos beta/administración & dosificación , Anciano , Alopurinol/administración & dosificación , Angioedema/inducido químicamente , Diuréticos/administración & dosificación , Hipersensibilidad a las Drogas/fisiopatología , Hipersensibilidad a las Drogas/terapia , Exantema/inducido químicamente , Gota/complicaciones , Gota/fisiopatología , Antagonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Hipertensión , Hiperuricemia , Fallo Hepático Agudo/inducido químicamente , Masculino , Terapia por Inhalación de Oxígeno , Insuficiencia Renal/inducido químicamenteRESUMEN
Steroid therapy is the third most common cause of osteoporosis, after loss of gonad function and senescence. The aim of the present study was to evaluate the protective action of clodronate on bone mass loss induced by steroid therapy. Sixty patients with bronchial asthma receiving either fluticasone (250 mg x 4/day) or beclomethasone (250 mg x 4/day) inhaled corticosteroid treatment were enrolled. Half the patients received combination treatment with clodronate (100 mg i.m./14 days), for a total period of 12 months. All patients were evaluated at baseline and at the end of treatment for bone mineral density (BMD) and calcium/phosphor metabolism parameters (kalemia, kaluria, phosphoremia, phosphaturia, alkaline phosphatase and hydroxyprolinuria over a 24-h period). The results of this preliminary study confirm the protective influence of clodronate on bone mass loss, as documented by the increment in mean values in BMD reported at the end of treatment compared with baseline values.
Asunto(s)
Androstadienos/efectos adversos , Asma/tratamiento farmacológico , Beclometasona/efectos adversos , Ácido Clodrónico/uso terapéutico , Osteoporosis/prevención & control , Administración por Inhalación , Anciano , Androstadienos/uso terapéutico , Antiasmáticos/efectos adversos , Antiasmáticos/uso terapéutico , Asma/fisiopatología , Beclometasona/uso terapéutico , Densidad Ósea/efectos de los fármacos , Enfermedad Crónica/tratamiento farmacológico , Fluticasona , Humanos , Bombas de Infusión , Masculino , Persona de Mediana Edad , Osteoporosis/inducido químicamenteRESUMEN
An increased traffic of circulating CD34+ Hemopoietic Precursors Cells (HPC) is an important feature of systemic allergic inflammation. Bacteria and bacterial products are capable of stimulating the transcription of the maturational cytokines IL12 and IFNs through the activation of Toll-Like-Receptor and the subsequent nuclear translocation of the NF-kappaB factor. In this study the probiotics differentiation/maturational effect potential on CD34+ HPC has been investigated. Fourteen consecutive subjects, 9M and 5F, aged 6-48, with clinical symptoms of asthma and /or conjunctivitis, rhinitis, urticaria, atopic dermatitis, food allergy and irritable bowel syndrome were enrolled. Allergen-specific serum IgE were found in twelve patients. Flow-cytometric measurement of peripheral blood CD34dim/bright HPC values were assessed before and after 30 days of therapy, consisting in the oral administration of one sachet a day of ENDOLAC (UCB Pharma, Turin, Italy). Each sachet contained a mixture of Lactobacillus acidophilus, L. delbrueckii and Streptococcus thermophilus for a total of 1 x 10(9) live bacteria. Circulating CD34+ cell values significantly (p < 0.001) reduced after the treatment. ENDOLAC, thus, may improve the efficacy of the standard treatments of allergic diseases.
Asunto(s)
Células Madre Hematopoyéticas/efectos de los fármacos , Hipersensibilidad Inmediata/terapia , Lactobacillus , Probióticos/farmacología , Streptococcus , Adolescente , Adulto , Especificidad de Anticuerpos , Antígenos CD34/análisis , Diferenciación Celular/efectos de los fármacos , Niño , Citocinas/biosíntesis , Femenino , Humanos , Hipersensibilidad Inmediata/sangre , Hipersensibilidad Inmediata/inmunología , Inmunoglobulina E/sangre , Síndrome del Colon Irritable/sangre , Síndrome del Colon Irritable/inmunología , Síndrome del Colon Irritable/terapia , Lactobacillus acidophilus , Masculino , Persona de Mediana EdadRESUMEN
An increased traffic of hematopoietic progenitor cells (HPC) between bone marrow and peripheral organs is a peculiar feature of the allergic inflammation. It has been recently reported that the sublingual form of specific immunotherapy (SLIT) is capable of reducing such an increased HPC traffic. The House Dust Mite major antigen Der p1 has been proved to up-regulate the expression of the ICAM-1 and VCAM-1 endothelial addressins, supporting the view of an inflammatory cell recruiting at the site of allergen extract administration. In the present work we have investigated, by flow-cytometric techniques, the expression of the two major integrins CD11a (LFA-1) and CD49d (VLA-4) that are the homing receptor cognate for ICAM-1 and VCAM-1 on human cord blood CD34 hematopoietic progenitor and stem cells. Even if both the investigated molecules resulted detectable on CD34+ HPC surfaces, being the system redundant, the density of the cellular expression was significantly higher for CD49d (median value: 158) than CD11a (median value: 20.5), suggesting a preferential usage of the homing axis VLA-4/VCAM-1. Results consistency with outcomes of clinical trials that relate SLIT efficacy to allergen dosage is discussed.
Asunto(s)
Antígeno CD11a/sangre , Desensibilización Inmunológica , Sangre Fetal/citología , Células Madre Hematopoyéticas/química , Integrina alfa4/sangre , Receptores Mensajeros de Linfocitos/sangre , Antígenos CD34/análisis , Células de la Médula Ósea/química , Células de la Médula Ósea/citología , Movimiento Celular , Relación Dosis-Respuesta Inmunológica , Citometría de Flujo , Interacciones Huésped-Parásitos/fisiología , Humanos , Recién Nacido , Integrina alfa4beta1/sangre , Molécula 1 de Adhesión Intercelular/metabolismo , Antígeno-1 Asociado a Función de Linfocito/sangre , Pyroglyphidae/fisiología , Molécula 1 de Adhesión Celular Vascular/metabolismoRESUMEN
BACKGROUND: The aim of this study is to clarify the prevalence of gallbladder benign neoplasms, their ultrasonographic appearance and their relationship with gallbladder lithiasis and cancer. METHODS: This study was carried out on 9000 consecutive patients having ultrasound of upper abdomen. Only adenomas and papillomas are considered as true benign neoplasms of the gallbladder. Adenomiomatosis and cholesterol polyps, often erroneously labelled as benign neoplasms, were excluded. Patients were followed-up by ultrasound every three months up to two years. RESULTS: The prevalence of benign neoplasms was 1.19%. Papillomas were found more frequently than adenomas both in males (68.51%) and in females (94.33%). Gallstones were not concomitant with benign neoplasms in any case. Neither stones nor growth of gallbladder benign neoplasms were recorded within the two-year follow-up period. CONCLUSIONS: Papillomas were more frequent than adenomas. No gallstone was concurrent with gallbladder benign neoplasms in our series. However, when gallstones are evidenced at ultrasound, further attention is recommended to discover probable concomitant neoplasms. Papillomas and adenomas more than 1 cm in diameter should be quarterly followed-up, while smaller masses could be six-monthly controlled. Surgery should be indicated for large-sized or rapidly growing masses because of the risk for cancer development.
Asunto(s)
Anestésicos Locales/toxicidad , Balanitis/inducido químicamente , Benzocaína/toxicidad , Condones/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Adulto , Balanitis/diagnóstico , Dermatitis Alérgica por Contacto/diagnóstico , Humanos , Masculino , Pruebas del Parche/métodosRESUMEN
In the last few decades, glucocorticoids have received increasing attention for their capability of provoking systemic hypersensitivity reactions, when administered orally, parenterally, or intralesionally, as well as allergic skin and mucosal symptoms, when applied locally to the skin in patients with contact dermatitis or to the mucosa in patients with asthma and/or rhinitis. However, because of their anti-inflammatory and immunosuppressive properties, glucocorticoids are often not suspected of such hypersensitivity reactions. In addition, because glucocorticoids retain their anti-inflammatory potential, even if they act as sensitizers, the signs and symptoms of allergic reactions are not always obvious, particularly when they overlap with those caused by the very diseases glucocorticoids are used to treat. Moreover, interpretation of diagnostic tests, specifically that of patch-test reactions, can be difficult. In this review, particular attention is addressed to the problem of allergenic cross-reactivity among topical and systemic glucocorticoids. We also look at the clinical and practical aspects of both cell-mediated and IgE-mediated hypersensitivity reactions to glucocorticoids and their consequences on anti-inflammatory therapeutic choices.